Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Phase 1
574
about 2.8 years
18+
5 sites in MI, TX, VA
About this study
This trial is testing a treatment called RMC-5127 for people with advanced solid tumors that have the KRAS G12V mutation. The trial will evaluate how safe and effective this treatment is, as well as its effects on the body's ability to process the drug.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take RMC-5127
- 2.Take cetuximab
- 3.Take daraxonrasib
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cetuximab
injection (Injection)
Primary: Dose Limiting Toxicities, Number of patients with adverse events (AEs)
Secondary: AUC concentrations of RMC-5127 and daraxonrasib, Cmax concentrations of RMC-5127 and daraxonrasib, Duration of Response (DOR), Half-Life of RMC-5127 and daraxonrasib, Objective Response Rate (ORR), Tmax concentration of RMC-5127 and daraxonrasib
Oncology